Perceptive Advisors SVRA Position
Active4-Fund ConvergencePerceptive Advisors initiated a new position in Savara Inc. (SVRA) in Q4 2025, holding $14.5M worth of shares across 2,400,000 shares.
SVRA is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Molgramostim in 440 days (Jun 30, 2027), making the timing of Perceptive's position particularly relevant.
Short interest stands at 13.4% of float with 17.1 days to cover, indicating significant bearish positioning against Perceptive's long thesis.
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Full company profile →Short Interest
13.4%
17.1 days to cover
Frequently Asked Questions
Does Perceptive Advisors own SVRA?
Yes. As of Q4 2025, Perceptive Advisors holds 2,400,000 shares of Savara Inc. (SVRA) valued at $14.5M. This data comes from their SEC 13F filing.
How many hedge funds own SVRA?
4 specialist biotech hedge funds currently hold SVRA, including Deerfield Management, RTW Investments, Driehaus Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy SVRA?
Perceptive Advisors's position in SVRA was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's SVRA position increasing or decreasing?
Perceptive Advisors initiated a new position in SVRA in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
SVRACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →